Raloxifene hydrochloride
|
|
|
- CAS-Nr.
- 82640-04-8
- Englisch Name:
- Raloxifene hydrochloride
- Synonyma:
- CS-127;ly156758;KEOXIFENE;LY 139481;AKOS 92138;RALOXIFENE HCL;LY156758 hydrochloride;LY139481 hydrochloride;Latilavir secondary VI;Evista (Raloxifene HCl)
- CBNumber:
- CB6302366
- Summenformel:
- C28H28ClNO4S
- Molgewicht:
- 510.04
- MOL-Datei:
- 82640-04-8.mol
|
Raloxifene hydrochloride Eigenschaften
- Schmelzpunkt:
- 250-253°C
- storage temp.
- 2-8°C
- Löslichkeit
- DMSO: 28 mg/mL, soluble
- Aggregatzustand
- solid
- Farbe
- light yellow
- maximale Wellenlänge (λmax)
- 286nm(lit.)
- Merck
- 14,8098
- BCS Class
- 2
- InChIKey
- BKXVVCILCIUCLG-UHFFFAOYSA-N
- SMILES
- C1(C(=O)C2C=CC(OCCN3CCCCC3)=CC=2)C2C=CC(O)=CC=2SC=1C1C=CC(O)=CC=1.Cl
- CAS Datenbank
- 82640-04-8(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Kennzeichnung gefährlicher |
Xi |
|
|
| R-Sätze: |
36/37/38 |
|
|
| S-Sätze: |
22-24/25 |
|
|
| WGK Germany |
3 |
|
|
| RTECS-Nr. |
PC4956925 |
|
|
| HS Code |
2934990002 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H351 |
Kann vermutlich Krebs verursachen. |
Karzinogenität |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
| P405 |
Unter Verschluss aufbewahren. |
| P501 |
Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Raloxifene hydrochloride Chemische Eigenschaften,Einsatz,Produktion Methoden
R-Sätze Betriebsanweisung:
R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut.
S-Sätze Betriebsanweisung:
S22:Staub nicht einatmen.
S24/25:Berührung mit den Augen und der Haut vermeiden.
Beschreibung
Raloxifene was launched as Evista in the US for the prevention of
postmenopausal osteoporosis. It is noteworthy that this molecule was formerly
under development as keoxifene for breast cancer and prostatic hypertrophy.
Raloxifene can be prepared by acylation of 6-methoxy-2-(4-methoxyphenyl)
benzothiophene followed by simultaneous demethylation of both methoxy
groups. Raloxifen is a selective estrogen receptor modulator, exerting antiestrogenic
action on certain tissues (breast) and also estrogenic action on bone
metabolism or serum lipids. In normal early postmenopausal women, 200 mg
daily produced a trend towards suppression of estrogen effects. Raloxifen
impeded bone loss in osteoporosis. A two-year study in postmenopausal women
with an increased risk for osteoporosis showed that Raloxifen markedly
prevented non-traumatic vertebral fractures. Results of several clinical studies
demonstrated that Raloxifen appreciably reduced the risk of developing breast
cancer. Moreover, it had favourable effect on lipid profiles without having the
potential side-effects of estrogen-based therapies. Several extensions for
different uses of this molecule are planned, for example growth disorder,
obesity, colon tumor and skin atrophy. No serious drug-related events have
been reported in the limited number of clinical trials.
Chemische Eigenschaften
Light-Yellow Solid
Verwenden
Raloxifene hydrochloride can be used as a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
Definition
ChEBI: A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.
Allgemeine Beschreibung
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Raloxifene hydrochloride Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Raloxifene hydrochloride Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 471)Lieferanten
| Firmenname |
Telefon |
E-Mail |
Land |
Produktkatalog |
Edge Rate |
|
Shanghai Worldyang Chemical Co.,Ltd.
|
,+86-21-56795779; +8613651600618
|
sales@worldyachem.com |
China |
879 |
58 |
|
Baoji Guokang Bio-Technology Co., Ltd.
|
0917-3909592 13892490616
|
gksales1@gk-bio.com |
China |
9339 |
58 |
|
Wuhan Godbullraw Chemical Co.,ltd
|
+undefined18986288449
|
Alisasales@godbullraw.com |
China |
560 |
58 |
|
Anhui Zhongda Biotechnology Co., Ltd
|
+8619956560829
|
justine@zhongda-biotech.com |
China |
300 |
58 |
|
Hong Kong Excellence Biotechnology Co., Ltd.
|
+86-86-18838029171 +8618126314766
|
ada@sh-teruiop.com |
China |
893 |
58 |
|
Anhui Ruihan Technology Co., Ltd
|
+8617756083858
|
daisy@anhuiruihan.com |
China |
994 |
58 |
|
zhuzhou dingcheng meihei comestic co.,ltd
|
+undefined18873369619
|
dingchengbusiness8@163.com |
China |
241 |
58 |
|
Sigma Audley
|
+86-18336680971 +86-18126314766
|
nova@sh-teruiop.com |
China |
525 |
58 |
|
Shanghai Aosiris new Material Technology Co., LTD
|
86-15139564871 +8615139564871
|
wrjmoon2000@163.com |
China |
352 |
58 |
|
Henan Tianfu Chemical Co.,Ltd.
|
+86-0371-55170693 +86-19937530512
|
info@tianfuchem.com |
China |
21691 |
55 |
82640-04-8()Verwandte Suche:
- RALOXIFENE HCL
- Raloxifene hydrochloride,Keoxifene hydrochloride, LY 156758, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride
- Raloxifene Hydrochloride (200 mg)
- 2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol hydrochloride
- (6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)Methanone hydrochloride
- Evista(Raloxifene Hydrochloride
- (6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)-(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanon
- [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone,hydrochloride (1:1)
- LY156758 (Keoxifene) HCl
- Evista (Raloxifene HCl)
- Methanone,[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride (1:1)
- (6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)-(4-(2-(piperidin-1-yl)ethoxy)phenyl)metha
- RALOXIFENE HYDROCHLORIDE
- KEOXIFENE
- KEOXIFENE HYDROCHLORIDE
- LY 139481
- AKOS 92138
- ly156758
- methanone,(6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidin
- [6-HYDROXY-2-(4-HYDROXYPHENYL)BENZO[B]THIEN-3-YL][4-[2-(1-PIPERIDINYL)ETHOXY]PHENYL]-METHANONE HYDROCHLORIDE
- [6-Hydroxy-2-(4-Hydroxyphenyl) benzo[b]thien-3-yl]
- RALOXIFENEHYDROCHLORIDE(SUBJECTTOPATENTFREE)
- Keoxifene hydrochloride, LY 156758, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride
- 6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl) ethoxy]phenyl]methanone HCl
- Raloxifene Hydrochloride Tablets
- LY156758 hydrochloride
- CS-127
- LY139481 hydrochloride
- Raloxifene hydrochloride,>98%
- [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
- Raloxifene hydrochloride USP/EP/BP
- Latilavir secondary VI
- Raloxifene hydrochloride Evista
- [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
- Raloxefene hydrochloride
- Raloxifene HCl (LY-139481)
- Raloxifene hydrochloride (Y0001134)
- Raloxifene Hydrochloride (1598201)
- (1aΞ,7aΞ)-1a-methyl-7a-[(2E,7RS,11RS)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-1a,7a-dihydronaphtho[2,3-b]oxirene-2,7-dione (trans-epoxyphytomenadione isomers)
- 82640-04-8
- 28640-04-8
- C28H27NO4S.HCl
- C28H27NO4SClH
- C28H27NO4SHClC28H28ClNO4S
- API
- Pharmaceutical intermediate
- Inhibitors
- antifungal
- Aromatics
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Sulfur & Selenium Compounds
- Active Pharmaceutical Ingredients
- Raloxifene
- Intracellular receptor
